Supplementary table 1 Clinical data of the female patients with and without diabetes (n) DiabetesNon-diabetes p value 58.6 ± 8.5 (3)54.3 ± 4.1 (3) 5.49.

Slides:



Advertisements
Similar presentations
Epidemiology of Diabetes Mellitus. Definition: -Diabetes mellitus is a group of diseases marked by high levels of blood glucose resulting from defects.
Advertisements

Type 2 Diabetes Glucose Management Goals 1. AACE Comprehensive Diabetes Care: Glucose Goals ParameterTreatment Goal for Nonpregnant Adults A1C (%)Individualize.
Fig. 4-1, p Fig. 4-2, p. 109 Fig. 4-3, p. 110.
Amelioration of Hyperalgesia by Gliclazide and Some Antioxidants in STZ diabetic Animals Hekma A. Abd El-Latif * Hekma A. Abd El-Latif * Abstract Neuropathy.
Slide 1Fig. 22.1, p.669. Slide 2Fig. 22.3, p.670.
Slide 1Fig. 17.1, p.513. Slide 2Table 17.1, p.514.
P.464. Table 13-1, p.465 Fig. 13-1, p.466 Fig. 13-2, p.467.
Fig. 11-1, p p. 360 Fig. 11-2, p. 361 Fig. 11-3, p. 361.
Table 6-1, p Fig. 6-1, p. 162 p. 163 Fig. 6-2, p. 164.
1 Diabetes. 2 Human Digestive System 3 Normal Regulation of Blood Glucose
Supplementary figure 1 Supplementary Fig. S1: Age dependent changes in db/db and db/dm mice. Representative images of PAS-stained kidney sections of db/db.
Figure 1.1 The observer in the truck sees the ball move in a vertical path when thrown upward. (b) The Earth observer views the path of the ball as a parabola.
Diabetes Edutool: Tutorial 4 The effect of exercise and insulin on blood glucose.
 Controls internal conditions, growth, development, and reproduction  Contains glands and organs that produces a chemicals and releases it into the.
Pancreas, Insulin & Diabetes In One Day 2015.
GENE THERAPY FOR DIABETES Lindsey Rowbotham Period 7.
Understanding Diabetes What is diabetes? Risk factors People without diabetes People with Type 1 diabetes People with Type 2 diabetes Signs and symptoms.
Diabetes
The Endocrine System Hormones and diabetes.
 By: Taylor Amenta, Lexi Cox, Grant Walters, Morgan Bradley.
TYPE 2 DIABETES BY: DOYIN. How to regulate the amount of glucose in the pancreas by Creating a new food Pyramid Diabetes is the lack of enough insulin.
Glucose in the Blood By: Paul.B, Carl.B, Joseph.G, Ace.C, Joshua.C.
1 Nervous System Endocrine System Chapter 15 – Endocrine System.
New method to differentiate human peripheral blood monocytes into insulin producing cells : Human hematosphere culture Supplementary Figures.
The FATZO mouse as a Translational Model for the Development of Drugs for Obesity, Metabolic Syndrome and Diabetes. PreClinOmics, Inc. 1.
Insulin By: Zach Seabrook (Dedicated to Adam DeKoning)
Normal Insulin Production Cells needs glucose Glucose is used by the mitochondria to make energy (ATP) After meals, glucose levels in the blood increase.
Body Composition The body’s proportion of fat and fat-free mass.
Each arrow in the diagram represents a different hormone released by the pituitary gland, which then stimulates another gland as indicated. All structures.
Evidence #1: Diabetes NEXT. Introduction Type 1 diabetes is a serious disease. It occurs when people stop producing a chemical called insulin. Insulin.
Do Now (on a separate sheet) 1. What is glucose? 2. Where does glucose go after entering the bloodstream? 3. What is the purpose of insulin?
Regulation of BloodGlucose. Blood filled with glucose (after eating) When blood glucose levels are high, the Pancreas secretes insulin which is a chemical.
Fig. 6-CO, p p. 185a p. 185b p. 185c p. 185d.
What is Microvascular Disease?
Mallahalli S. Manu, Kuruvanthe S. Rachana, Gopal M. Advirao
Chapter 12 Endocrine System.
Evidence #1: Diabetes NEXT.
Volume 4, Issue 12, Pages (December 2015)
Mean rates of insulin and glucagon delivery from an artificial pancreas at various blood glucose levels. The device was programmed to establish and maintain.
Figure S1 Mean and 95% confidence interval for the mean of tumor protein 53 (p53; Fig.S1a), mouse double minute 2 (MDM2; Fig.S1b), glucose transporter.
Patient A.
Program Goals. Inhaled Insulin: Overcoming Past Obstacles With Advances in Understanding.
The Endocrine System.
The Endocrine System and Assessment
Gerry H. Tan, M.D., Roger L. Nelson, M.D.  Mayo Clinic Proceedings 
Fig. 1. Glycemic variability in three hypothetical patients who have the same mean blood glucose concentration. Patient B has relatively small variations.
Better Diabetes Control With Novel Basal Insulins
Relationship between plasma glucose, insulin and glucagon levels
Solitary Fibrous Tumor Associated With Non-Islet Cell Tumor Hypoglycemia  Kotaro Kameyama, MD, Norihito Okumura, MD, Yujiro Kokado, MD, Kentaroh Miyoshi,
Change in random blood glucose level, body weight, and intraperitoneal glucose tolerance test (IPGTT) in streptozotocin (STZ)-induced diabetic mice. Change.
Knowledge Organiser – Hormonal control in humans
Volume 15, Issue 3, Pages (October 2008)
Evidence #1: Diabetes NEXT.
Fig. 6-CO, p. 211.
07CO, p. 190.
a b c d e Moriguchi et al., Supplementary Fig. S1
1018-NT-β-cell clusters protect mice from STZ-induced diabetes.
WASH cKO mice display a normal pancreatic development.
Significant pathological changes and activation of Nrf2 pathway in the glomeruli of human diabetic nephropathy patients. Significant pathological changes.
Nrf2−/− mice had higher TGF-β1 transcription and FN expression.
Nrf2−/− mice suffered greater renal damage by STZ compared with Nrf2+/+ mice. Nrf2−/− mice suffered greater renal damage by STZ compared with Nrf2+/+ mice.
Comparison of women carrying a male fetus and those carrying a female fetus, with respect to mean adjusted blood glucose levels during the OGTT (A), mean.
Effects of the β-cell–specific expression of mKL on blood glucose levels, glucose tolerance, insulin sensitivity, and plasma insulin levels in STZ-induced.
A: Representative Western blot showing a band migrating at ∼90 kDa corresponding to neprilysin protein. A: Representative Western blot showing a band migrating.
A: Chemical structure of pterosin A
Chop deletion preserves β-cell function in P58IPK−/− mice.
* * * ** ** ** ** ** ** Fig. 1..
Mice lacking Y1 receptor in the hematopoietic compartment remain healthy under normal chow feeding conditions. Mice lacking Y1 receptor in the hematopoietic.
Evidence #1: Diabetes NEXT.
Time course of daily basal and mealtime insulin dose (A), glycated hemoglobin (B), laboratory-measured clinic FPG (C), prebreakfast SMPG (D), SMPG profiles.
Presentation transcript:

Supplementary table 1 Clinical data of the female patients with and without diabetes (n) DiabetesNon-diabetes p value 58.6 ± 8.5 (3)54.3 ± 4.1 (3) 5.49 ± 0.23 (3)7.33 ± 0.37 (3) Female Age (years) FPG (mM) <0.05 >0.05

Supplementary Fig Cont (n=5) STZ (n=5) Body weight (g) (Day) (Day) Cont (n=5) STZ (n=5) Blood glucose (mM) * * *** * * * * * *

Normal Diabetes Supplementary Fig. 2A A 100 μm200 μm100 μm200 μm Nrf2 Insulin Merged Human (male)

Supplementary Fig. 2B 200 μm 100 μm NormalDiabetes 200 μm 100 μm Human (female) B

100 μm Normal Diabetes C Mouse (male) Nrf2 Insulin Merged 200 μm100 μm200 μm Supplementary Fig. 2C

NQO1 positive cells (%) * * * p<0.05 H 2 O 2 Dh404     50  m ControlDh404 H2O2H2O2 H 2 O 2 + dh404 Supplementary Fig. 3 NQO-1

p62 β-actin LC3-II Ub-proteins p62 β-actin LC3-II Ub-proteins Soluble Insoluble FBS H 2 O 2  0h0h1h1h6h6h12h24h         FBS H 2 O 2  0h0h1h1h6h6h12h24h         p62 β-actin LC3-II p62 LC3-II β-actin Ub-proteins Dh404   Soluble Insoluble Ub-proteins A B Supplementary Fig. 4 kDa kDa

Supplementary Fig µm 100 µm 250 µm 50 µm 100 µm 250 µm Dithizone staining A Glucose mM25 mM Insulin release (mU/IEQ) * 100 µm 50 µm 100 µm 50 µm B C   Anti-insulin & proinsulinAnti-glucagon